A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TAK-491 when co-administered with chlorthalidone [chlortalidone] in subjects with essential hypertension.

Trial Profile

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TAK-491 when co-administered with chlorthalidone [chlortalidone] in subjects with essential hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Azilsartan medoxomil; Chlortalidone
  • Indications Essential hypertension; Hypertension
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 May 2010 Primary endpoint 'Systolic blood pressure' has been met.
    • 01 May 2010 Primary endpoint 'Ambulatory blood pressure' has been met.
    • 01 May 2010 Results were presented at the 25th Annual Scientific Meeting of the American Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top